Background Shunting of glycolytic intermediates into the pentose phosphate pathway has been suggested to protect from hyperglycaemiainduced microvascular damage. We hypothesized that genetic variability in the gene encoding transketolase, a key pentose phosphate pathway enzyme, contributes to early nerve dysfunction in recent-onset diabetes.
Introduction
Diabetic sensorimotor polyneuropathy (DSPN) is a serious complication of diabetes encountered in about one-third of all diabetic patients [1] and predictor of feared endpoints such as diabetic foot ulcers [2] , cardiovascular morbidity [3] , and mortality [4] . Four major molecular pathways have been implicated in glucose-mediated microvascular complications triggered by a single hyperglycaemia-induced process of overproduction of superoxide by the mitochondrial electron-transport chain [5] . Superoxide overproduction partially inhibits the glycolytic enzyme glyceraldehyde phosphate dehydrogenase (GAPDH), thereby diverting upstream metabolites from glycolysis into glucose-driven signalling pathways of glucose overuse.
Fructose-6-phosphate and glyceraldehyde-3-phosphate are two of these upstream metabolites which are also end products of the non-oxidative branch of the pentose phosphate pathway (PPP) [6] . These metabolites are generated by the thiamine diphosphate-dependent enzyme transketolase that catalyses several key reactions of the nonoxidative branch of the PPP and serves as a bridge between the oxidative part of PPP and oxidative decarboxyl metabolism of glucose, allowing the cell to adapt to a variety of metabolic needs under different environmental conditions [7] . Under physiological conditions, transketolase enzyme activity operates approximately proportional to substrate concentration [8] . Hyperglycaemiainduced rise in fructose-6-phosphate and glyceraldehyde-3-phosphate concentrations diverts these metabolites to pentose-5-phosphates and erythrose-4-phosphate under conditions where transketolase is fully activated by its cofactor thiamine [6] . Indeed, transketolase activation in retinas of diabetic animals inhibited three of the four major biochemical pathways implicated in the pathogenesis of hyperglycaemia-induced microvascular damage and prevented experimental diabetic retinopathy [6] . Thus, transketolase activation may limit the turnover of damaging pathways by reducing the availability of their precursors [9] .
Evidence has accumulated suggesting that thiamine metabolism is altered in diabetes, but it remains unclear which mechanisms contribute most to the deficient action of thiamine [10] . Patients with type 1 and type 2 diabetes frequently showed low plasma thiamine concentrations in association with increased thiamine clearance, while erythrocyte transketolase activity was not reduced but correlated inversely with urinary albumin excretion [11] . In contrast, a decrease in basal erythrocyte transketolase activity without evidence of thiamine deficiency was observed in diabetic patients with polyneuropathy [12] . Early work suggested that transketolase activity was inhibited by plasma, cerebrospinal fluid, and low molecular weight dialysate fractions obtained from patients with uremic neuropathy. Data of clinical grading of the neurological deficits and values of motor nerve conduction velocity revealed a correlation between the extent of uremic neuropathy and the degree of nervous tissue transketolase inhibition [13] .
In a recent study, progression of nephropathy and incidence of major cardiovascular events were associated with genetic variability in the transketolase enzyme in diabetic patients [9] , but no data addressing such a possible relationship to diabetic neuropathy is available. Because shunting of glycolytic intermediates into the PPP has been suggested to protect from hyperglycaemia-induced microvascular damage, we hypothesized that genetic variability in transketolase, one of the key PPP enzymes, could contribute to early nerve dysfunction in individuals with recent-onset diabetes.
Materials and methods
The study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of Heinrich Heine University, Düsseldorf, Germany. All participants provided a written informed consent. Included were 538 participants of the German Diabetes Study (GDS) baseline cohort, 165 and 373 of whom had type 1 and type 2 diabetes, respectively. The GDS is a long-term prospective observational study assessing the long-term course of diabetes and its sequelae (ClinicalTrials.gov Identifier: NCT01055093) [14] . Inclusion criteria for entry into the GDS are type 1 or type 2 diabetes, known diabetes duration of ≤1 year and age of 18-69 years at baseline assessment. Exclusion criteria for the present study were type 3 diabetes, pregnancy, severe diseases (e.g. cancer), psychiatric disorders, immunosuppressive therapy, limited cooperation ability, and neuropathy from causes other than diabetes.
Single nucleotide polymorphisms (SNPs) of tagging SNPs was based on publicly available data of the International 1000 genomes Project derived from Utah residents with Central European ancestry http:// 1000genomes.org. We screened in silico the complete transketolase gene spanning 53258723-53290130 (chromosome assembly GRCh37.p13) on chromosome 3. We found 76 SNPs with a minor allele frequency (MAF) ≥0.2. Among these, 13 tagging SNPs were selected for genotyping using tagger software from haploview freeware (https://www.broadinstitute.org/scientificcommunity/science/programs/medical-and-populationgenetics/haploview/haploview). Genotyping was successful for nine of these SNPs. The nine tagging SNPs covered 73% of all common genetic variation in the locus (MAF ≥0.2). The nine transketolase tagging SNPs were genotyped using the Sequenom massARRAY system with iPLEX software (Sequenom, Hamburg, Germany) as previously described [15] . The genotyping success rates were 99.7%. The Sequenom results were validated by bidirectional sequencing in 50 randomly selected subjects, and both methods gave 100% identical results (r = 1.00).
Neurophysiological and clinical measures
Peripheral nerve function tests were performed as previously described [16] . In brief, motor nerve conduction velocity (NCV) was measured in the median, ulnar, and peroneal nerves, while sensory NCV and sensory nerve action potentials (SNAP) were determined in the median, ulnar, and sural nerves at a skin temperature of 33-34°C using surface electrodes (Nicolet VikingQuest, Natus Medical, San Carlos, CA). Quantitative sensory testing included measurement of the vibration perception threshold (VPT) at the second metacarpal bone and medial malleolus using the method of limits (Vibrameter, Somedic, Stockholm, Sweden) and thermal detection thresholds (TDT) including warm and cold thresholds at the thenar eminence and dorsum of the foot using the method of limits (TSA-II NeuroSensory Analyzer, Medoc, Ramat Yishai, Israel). Neurological examination was performed using the Neuropathy Disability Score (NDS) and Neuropathy Symptom Score (NSS) [17] . DSPN was defined according to modified Toronto Consensus criteria [18] including subclinical DSPN (stage 1a), asymptomatic DSPN with neuropathic signs but without neuropathic symptoms (stage 1b), and symptomatic DSPN with neuropathic symptoms with or without neuropathic signs (stage 2). Confirmed DSPN was defined by the presence of ≥2 abnormal nerve conduction attributes <2.5th percentile with ≥1 being peroneal MNCV, sural SNCV, or sural SNAP.
Plasma methylglyoxal was determined by HPLC after derivatization with 1,2-diamino-4,5-dimethoxybenezene as previously described [19] . To prevent overestimation of MG levels by peroxidases and trace metals, derivatization was performed in the presence of sodium azide and DETAPAC as suggested previously [20] .
Statistical analysis
Comparisons between type 1 and type 2 diabetes subjects were performed using the non-parametric t-test (MannWhitney U test) for continuous variables and Fisher's exact test or χ 2 test where appropriate for categorical variables. Associations of SNPs with measures of DSPN were studied by the Kruskal-Wallis test. Considering that 9 SNPs and 18 neurological measures were investigated, P values were adjusted for multiple comparisons using the Bonferroni correction. All statistical tests were performed two sided. The level of significance before and after Bonferroni correction was set at α = 0.05 and α = 0.0003 (0.05/162 = 0.0003), respectively. Statistical analyses were performed using IBM SPSS Statistics 22 software.
Results
The demographic and clinical characteristics of the two groups studied are listed in Table 1 . Compared to type 1 diabetic patients, those with type 2 diabetes were older and showed higher BMI, waist circumference, systolic and diastolic blood pressure, triglycerides, LDL cholesterol, albuminuria, NSS, NDS, metacarpal and malleolar VPT, and TDT to warm and cold stimuli on the hand and foot as well as lower HDL cholesterol, HbA 1c , peroneal and median MNCV, median SNCV, and sural, median, and ulnar SNAP (all P < 0.05). No significant differences between the groups were observed for sex, heart rate, serum creatinine, known diabetes duration, percentages of smokers, TSS in the feet, ulnar MNCV, sural SNCV, and ulnar SNCV.
The allele distributions in the nine transketolase tagging SNPs are shown in Table 2 . All SNPs were in Hardy-Weinberg Equilibrium. The associations of transketolase SNPs with neuropathic symptoms and neurophysiological parameters that achieved statistical significance are shown in Table 3 . In the entire group before Bonferroni correction, TSS in the feet was associated with transketolase SNPs rs7648309, rs62255988, and rs7633966, while peroneal MNCV correlated with rs7648309 (all P < 0.01). Cold TDT (foot) was associated with transketolase SNPs rs11130362 and rs7648309, while warm TDT (hand) correlated with rs62255988 and rs7648309 (all P < 0.01). After Bonferroni correction, the correlations of transketolase SNP rs7648309 with TSS (P = 0.024) and rs62255988 with warm TDT (hand) (P = 0.049) remained statistically significant. In the group with type 1 diabetes before Bonferroni correction, TSS in the feet was associated with transketolase SNP rs62255988, while peroneal MNCV correlated with rs7648309, rs9284890, rs12629312, and rs9820979 (all P < 0.05). Moreover, median MNCV was associated with rs9284890, while ulnar SNCV was linked with transketolase SNP rs12629312 and warm TDT (hand) to rs7648309 (all P < 0.05). In the group with type 2 diabetes before Bonferroni correction, TSS (foot) was associated with transketolase SNPs rs7648309, rs62255988, and rs7633966 (all P < 0.05). Furthermore, metacarpal VPT correlated with transketolase SNP rs9820979, while cold TDT (foot) was related to rs11130362 and rs7648309, and warm TDT (hand) correlated with rs7648309 and rs62255988 (all P < 0.01). After Bonferroni correction, the associations in each diabetes group were no longer statistically significant.
The P values for the associations of transketolase SNPs with the TSS and neurophysiological parameters separately according to sex are shown in Table 4 . In the entire male group before Bonferroni correction, TSS in the feet was associated with transketolase SNPs rs7648309, rs62255988, and rs7633966, while peroneal MNCV correlated with rs7648309 (all P < 0.01). Cold TDT (foot) was associated with transketolase SNPs rs11130362 and rs7648309, while warm TDT (hand) correlated with rs62255988 and rs7648309 (all P < 0.05). After Bonferroni correction, the correlations between the TSS and transketolase SNP rs7648309 (P = 0.013) and rs62255988 (P = 0.005) with TSS remained statistically significant. In the entire female group before Bonferroni correction, only peroneal MNCV was associated with transketolase SNPs rs7648309 and rs9284890 (P < 0.01), but statistical significance was lost after Bonferroni correction. In the male type 1 diabetes group before Bonferroni correction, only peroneal MNCV correlated with transketolase SNP rs7648309 (P = 0.041), while in women with type 1 diabetes peroneal MNCV correlated with rs7648309, rs9284890, and rs9820979 (all P < 0.05) and ulnar SNCV was associated with rs12629312 (P = 0.004), but statistical significance was lost after Bonferroni correction. In the male group with type 2 diabetes before Bonferroni correction, TSS in the feet was associated with transketolase SNPs rs7648309, rs62255988, and rs7633966, while peroneal MNCV correlated with rs7648309 (all P < 0.05). Cold TDT (foot) was associated with transketolase SNPs rs11130362 and rs7648309, while warm TDT (hand) correlated with rs62255988 and rs7648309 and metacarpal VPT correlated with rs9820979 (all P < 0.05). After Bonferroni correction, the correlations between the TSS and transketolase SNP rs7648309 (P = 0.036) and rs62255988 (P = 0.031) with TSS remained statistically significant. In the female group with type 2 diabetes only peroneal MNCV and transketolase SNP rs9284890 were associated (P = 0.029), but statistical significance was lost after Bonferroni correction.
Supplementary Table 1 shows the percentages with 95% confidence intervals of patients with confirmed DSPN and abnormal neurophysiological tests (<2.5th or >97.5th percentile of control subjects) for the SNPs listed in Table 2 . Peroneal MNCV correlated with transketolase SNP rs9284890, while warm TDT hand was associated with rs62255988 and DSPN correlated with rs9284890 (all P < 0.05), but statistical significance was lost after Bonferroni correction. Table 5 shows the relationship between transketolase SNPs and plasma methylglyoxal concentrations. No associations were observed between each of the nine tagged transketolase SNPs and plasma methylglyoxal levels.
Discussion
The results of this study demonstrate associations of genetic variability in transketolase enzyme with neuropathic symptoms and reduced thermal detection threshold in recently diagnosed diabetic patients with known diabetes duration up to 1 year, suggesting a role of pathways metabolizing glycolytic intermediates in early diabetic nerve dysfunction. Subgroup analysis stratified by sex and diabetes type revealed that these associations were determined primarily by male sex and type 2 diabetes.
To our knowledge, genetic variability in transketolase enzyme has not been previously described in the context of diabetic polyneuropathy. Only two reports from a single institution have addressed the role of genetic variation in the transketolase enzyme in diabetic patients with various stages of nephropathy. The first report focused on concentrations of thiamine and its esters in plasma and whole blood and transketolase-catalysed reaction together with 14 tagging SNPs in the transketolase, transaldolase, and transketolase-like 1 (TKTL-1) genes. Among 240 subjects studied with variable degrees of nephropathy, 69 had type 1 diabetes, 4 had latent autoimmune diabetes in adults (LADA), and 167 had type 2 diabetes. Among 10 tagging SNPs in the transketolase gene, there were no differences in allelic, genotype, or haplotype distributions between groups of diabetic patients with and without nephropathy. Moreover, no associations were found between genotypes of all 10 SNPs in the transketolase locus and transketolase activity in erythrocytes [21] . In the second report from the same institution, 19 SNPs in six genes encoding enzymes metabolizing glycolytic intermediates produced in excess under hyperglycaemic conditions (transketolase, transaldolase, TKTL-1, fructosamine 3-kinase (FN3K), glyoxalase 1, and glucose-6-phosphate dehydrogenase) were analysed in 314 type 2 diabetic subjects with variable stages of nephropathy who were followed up for a median of 38 months. Progression of diabetic nephropathy was Values in bold indicate differences between groups (P < 0.05; Kruskal-Wallis test). *P = 0.024, and **P = 0.049 after Bonferroni correction. TSS, Total Symptom Score; MNCV, motor nerve conduction velocity; SNCV, sensory nerve conduction velocity; VPT, vibration perception threshold; TDT, thermal detection threshold. Values in bold indicate differences between groups (P < 0.05; Kruskal-Wallis test). *P = 0.013, **P = 0.005, + P = 0.036, and ++ P = 0.031 after Bonferroni correction. TSS, Total Symptom Score; MNCV, motor nerve conduction velocity; SNCV, sensory nerve conduction velocity; SNAP, sensory nerve action potential; VPT, vibration perception threshold; TDT, thermal detection threshold.
predicted by a combination of transketolase SNP rs11130362 and FN3K SNP rs1056534. In addition, transketolase SNP rs3736156 alone and also in combination with the previous two SNPs predicted the incidence of major cardiovascular events. No such a predictive value was observed for the remaining SNPs [9] . Thus, among SNPs in genes encoding enzymes metabolizing glycolytic intermediates, primarily transketolase SNPs may have an impact on the development of micro-and macrovascular damage. Our results add to the current knowledge by linking clinical and neurophysiological measures of polyneuropathy such as neuropathic symptoms and reduced thermal sensation at an early stage of diabetes to differences between genotypes of transketolase SNPs rs7648309 and rs62255988. Moreover, we found that differences between genotypes of these SNPs were associated with neuropathic symptoms preferentially in male individuals with type 2 diabetes.
Evidence has emerged to suggest that diabetic microvascular complications including neuropathy are caused by activation of four major pathways comprising the polyol pathway, advanced glycation end-product (AGE) formation with subsequent activation of the receptor for AGEs (RAGE) [22] and nuclear factor κB [23] , protein kinase C (PKC) isoforms, and hexosamine pathway by mitochondrial overproduction of superoxide [5] . Transketolase can limit the activation of these pathways by lowering availability of their precursors [6] . Cells in general are capable of either decreasing oxidative stress by enzymatic and non-enzymatic antioxidant mechanisms and/or eliminating of damaging metabolites and their substrates (generated by overloaded glycolysis) that accumulate within cells. Such an alternative pathway for glucose oxidation is PPP which fulfils three important functions: first, production of reducing equivalent NADPH necessary for reduction of oxidized glutathione thus supporting intracellular antioxidant defence; second, production of ribose-5-phosphate required for the synthesis of nucleotides; and third, metabolic use of dietary pentoses. PPP consists of two branches: an irreversible oxidative branch necessary for NADPH and production of pentose phosphates and a reversible non-oxidative branch in which interconversion of three to seven carbons containing sugars occurs [7, 8, 10] . Transketolase, one of the key enzymes of the non-oxidative branch of PPP, transports 2-carbon units and catalyses formation of ribose-5-phosphate from glycolytic intermediates. Transketolase is activated by its cofactor thiamine and its derivative benfotiamine which has been shown to prevent experimental diabetic retinopathy by blocking the aforementioned major pathways responsible for hyperglycaemiainduced microvascular damage via the regulation of PPP resulting in diminished accumulation of triosephosphates and fructose-6-phosphate [6, 10, 24] . Several lines of evidence point to deficient action of thiamine in diabetes, but the mechanisms responsible for this finding remain currently unclear.
An enhanced metabolic flux leads to an increase in reactive carbonyl species via accumulation of triosephosphate intermediates. Methylglyoxal pertains to a class of reactive carbonyl species known as the alphaoxoaldehydes or dicarbonyls. It is formed from the spontaneous degradation of triosephosphate intermediates and is a highly potent glycating agent [25, 26] . Dicarbonyls such as methylglyoxal modify DNA and react with amino groups of intracellular and extracellular proteins to form advanced glycation end products (AGEs). Increased formation of AGEs results in enhanced cellular stress, dysfunction and ultimately cell death. The interaction of AGE-modified proteins through cell surface receptors, such as RAGE, can lead to increased cellular activation and sustained inflammatory responses [27] . In diabetic subjects the concentrations of intracellular triosephosphate intermediates and methylglyoxal in erythrocytes are excessively elevated as compared to healthy controls [26] . In experimental diabetic [28] . These findings suggest that the direct and indirect effects of dicarbonyls on nerves or neuronal microvascular network provide a unifying mechanism for the development and progression of diabetic neuropathy [27] . Here we hypothesized that, if genetic variability in the transketolase enzyme would slow down the turnover of PPP, this could be linked to an increased flux through the AGE pathway. Thus, we would have expected that transketolase SNPs are related to elevated methylglyoxal levels. However, our results do not support this notion, because we found no associations between each of the nine tagged transketolase SNPs and plasma methylglyoxal concentrations. One possible explanation for the lack of such an association could be that plasma methylglyoxal levels do not readily reflect intracellular methylglyoxal metabolism. In this context, it could be useful to determine cytosolic methylglyoxal concentrations and glyoxalase 1 activity, e.g. in mononuclear cells, to further address our hypothesis. The present study has several limitations. First, we did not measure parameters of thiamine metabolism to explore a possible genotype-phenotype interaction between the latter and transketolase SNPs in relation to diabetic neuropathy. The two main tests routinely used for the assessment of thiamine status are the measurement of erythrocyte transketolase activity and the so-called thiamine effect. The former is measured by a kinetic reaction without adding thiamine. The thiamine effect has been defined as an increase of transketolase activity ≤15% after addition of a saturating amount of thiamine diphosphate (TDP) to the reaction [10] . However, neither erythrocyte transketolase activity nor the thiamine effect were altered in subjects with diabetes compared to controls or in diabetic individuals with vs those without microalbuminuria [11] . In contrast, low plasma thiamine concentrations were relatively frequent in patients with type 1 and type 2 diabetes presumably because of an increased thiamine clearance [11] . However, it has been argued that plasma thiamine predominantly reflects thiamine intake rather than cellular levels [10] . Second, the cross-sectional study design does not allow to determine the predictive value of transketolase SNPs on the development and progression of diabetic neuropathy which has to be verified in long-term prospective studies. The strengths of this work are the relatively large, homogeneous, and extensively phenotyped early-onset diabetes groups and comprehensive quantitative assessment of peripheral nerve function.
In conclusion, this study demonstrates associations of genetic variability in transketolase, a rate-limiting enzyme of pathways proposed to confer hypothetical protection against hyperglycaemia, with neuropathic symptoms and reduced thermal sensation in recently diagnosed diabetes. These associations were mainly driven by male sex and type 2 diabetes. Treatment with thiamine and its derivatives has been shown to augment PPP activity [10] , normalize biomarkers of pathways causing microvascular complications in patients with type 1 diabetes [29] , ameliorate neuropathic symptoms [30] [31] [32] , and improve NCV in one study [33] , but not in another [34] , albeit the latter trial has been criticized for using a questionable study design [35] . Thus, pharmacogenomics considering transketolase SNPs could be useful to optimize such treatments in the future. appropriately investigated and resolved. DZ is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
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